Home » Stocks » TTNP

Titan Pharmaceuticals, Inc. (TTNP)

Stock Price: $0.190 USD 0.023 (14.05%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $0.181 -0.009 (-4.53%) Nov 25, 7:59 PM

Stock Price Chart

Key Info

Market Cap 37.37M
Revenue (ttm) 5.00M
Net Income (ttm) -19.10M
Shares Out 196.76M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $0.190
Previous Close $0.167
Change ($) 0.023
Change (%) 14.05%
Day's Open 0.160
Day's Range 0.156 - 0.214
Day's Volume 118,413,202
52-Week Range 0.094 - 0.545

More Stats

Market Cap 37.37M
Enterprise Value 38.63M
Earnings Date (est) Apr 5, 2021
Ex-Dividend Date n/a
Shares Outstanding 196.76M
Float 196.30M
EPS (basic) n/a
EPS (diluted) -0.24
FCF / Share -0.17
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14.79M
Short Ratio 0.71
Short % of Float 7.54%
Beta 0.91
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.48
PB Ratio 14.52
Revenue 5.00M
Operating Income -17.08M
Net Income -19.10M
Free Cash Flow -16.95M
Net Cash -1.27M
Net Cash / Share -0.01
Gross Margin -98.42%
Operating Margin -341.70%
Profit Margin -382.10%
FCF Margin -339.10%
ROA -160.23%
ROE n/a
ROIC -391.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$0.80*
Low
0.80
Current: $0.190
High
0.80
Target: 0.80
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.616.620.2215.071.673.6510.487.124.0710.09
Revenue Growth-45.44%2978.14%-98.57%801.56%-54.17%-65.21%47.27%74.95%-59.69%-
Gross Profit2.326.080.2215.071.673.6510.487.124.0710.09
Operating Income-16.84-8.26-14.504.34-6.76-3.48-0.89-8.37-10.51-6.03
Net Income-16.46-9.02-14.315.14-11.28-2.409.71-15.18-15.20-6.83
Shares Outstanding22.965.693.533.463.342.842.492.011.791.79
Earnings Per Share-0.72-1.66-4.221.20-3.36-1.203.18-7.62-9.28-2.98
Operating Cash Flow-15.45-8.43-12.686.29-7.47-5.87-9.801.83-14.48-4.66
Capital Expenditures-0.26-0.42-0.18-0.17-0.13-0.02-0.32-1.15-0.23-0.03
Free Cash Flow-15.70-8.85-12.856.12-7.60-5.88-10.120.68-14.71-4.69
Cash & Equivalents5.229.667.8814.017.8615.4711.8018.105.413.18
Total Debt4.444.316.58----11.8612.257.27
Net Cash / Debt0.785.341.3014.017.8615.4711.806.24-6.85-4.09
Assets9.5214.108.9118.6713.2920.8518.4224.8310.224.75
Liabilities8.097.268.055.486.3012.2412.6647.9630.3010.81
Book Value1.436.830.8613.196.998.615.76-23.13-20.08-6.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Titan Pharmaceuticals, Inc.
Country United States
Employees 21

Stock Information

Ticker Symbol TTNP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TTNP
IPO Date January 18, 1996

Description

Titan Pharmaceuticals, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.